Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Henlius Biotech Co. Ltd.

https://www.henlius.com/en/index.html

Latest From Shanghai Henlius Biotech Co. Ltd.

Henlius Kicks Off Denosumab Trial

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

Biosimilars Clinical Trials

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Biosimilars Deals

Cancer, Rare Disease Drugs Among New China Approvals

Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.

Approvals China

Henlius’ Trastuzumab Approved In China

Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.

Biosimilars Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Fosun Pharma
    • Henlius Biopharmaceuticals
    • Shanghai Henlius Biotech, Inc.
    • Taiwan Henlix Biotech Co., Ltd.
    • Hengenix Biotech
UsernamePublicRestriction

Register